Multiple Myeloma

Anderson, Kenneth C.; Alsina, Melissa; Bensinger, William I.; Biermann, J. Sybil; Chanan‐Khan, Asher; Cohen, Adam D.; Devine, Steven M.; Djulbegoviĉ, Benjamin; Faber, Edward A.; Gasparetto, Cristina; Huff, Carol Ann; Kassim, Adetola A.; Medeiros, Bruno C.; Meredith, Ruby F.; Raje, Noopur; Schriber, Jeffrey; Singhal, Seema; Somlo, George; Stockerl-Goldstein, Keith; Treon, Steven P.; Tricot, Guido; Weber, Donna M.; Yahalom, Joachim; Yunus, Furhan

doi:10.6004/jnccn.2011.0095

Cited by 58 publications

(55 citation statements)

References 105 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MM remains incurable; however, the response rate, progression-free survival (PFS) and overall survival (OS) have significantly improved due to the introduction of initial treatment incorporating novel agents such as thalidomide, lenalidomide and bortezomib, and autologous stem cell transplantation (auto-SCT) [2,3,4]. Based on the results from randomized phase III studies, the National Comprehensive Cancer Network guidelines recommended the use of thalidomide, lenalidomide and bortezomib in the treatment of both transplant-eligible and noneligible patients [5,6]. Thus, novel agents have become the standard of care for symptomatic MM as primary therapy and salvage therapy.…”

Section: Introductionmentioning

confidence: 99%

Survival of Multiple Myeloma Patients Aged 65-70 Years in the Era of Novel Agents and Autologous Stem Cell Transplantation

Ozaki¹,

Harada²,

Saitoh³

et al. 2014

Acta Haematol

View full text Add to dashboard Cite

Novel agents such as thalidomide, lenalidomide and bortezomib have dramatically changed the treatment paradigm of multiple myeloma (MM). However, it is not clear whether these agents improve the prognosis of elderly patients who have undergone autologous stem cell transplantation (auto-SCT). We retrospectively analyzed the outcome of 318 newly diagnosed patients aged 65-70 years who were treated between January 1, 2004, and December 31, 2009. As initial therapy, 192 patients were treated with conventional chemotherapy, 88 with novel agent-containing regimens, 21 with conventional chemotherapy plus auto-SCT and the remaining 17 with novel agents plus auto-SCT. The median progression-free survival was 19.1, 24.5, 26.8 and 35.2 months, respectively, and the 5-year overall survival (OS) was 40, 62, 63 and 87%, respectively. Initial therapy with novel agents (p < 0.001) or auto-SCT (p < 0.02) significantly improved OS compared with the group without these treatment modalities. Salvage therapy with novel agents also significantly improved survival after relapse compared with conventional chemotherapy alone (p < 0.04). In a multivariate analysis, the use of novel agents was an independent prognostic factor significantly associated with extended OS (p < 0.003). These results indicate that novel agents and auto-SCT had a major impact on OS in eligible patients in this subgroup of MM.

show abstract

Section: Introductionmentioning

confidence: 99%

Survival of Multiple Myeloma Patients Aged 65-70 Years in the Era of Novel Agents and Autologous Stem Cell Transplantation

Ozaki¹,

Harada²,

Saitoh³

et al. 2014

Acta Haematol

View full text Add to dashboard Cite

show abstract

“…While there are a number of new drugs for treating relapsed disease, a second transplant remains a viable treatment option for patients and should be considered in the arsenal of available therapeutic options for these patients. Current NCCN guidelines recommend that all patients who are eligible for auto-HCT be considered for peripheral blood apheresis sufficient for two autografts in the event a second autograft is necessary in the salvage setting [95].…”

Section: Accepted Manuscriptmentioning

confidence: 99%

Hematopoietic Stem Cell Transplantation for Multiple Myeloma: Guidelines from the American Society for Blood and Marrow Transplantation

Shah

Callander

Ganguly

et al. 2015

Biology of Blood and Marrow Transplantation

Self Cite

111

View full text Add to dashboard Cite

Therapeutic strategies for multiple myeloma (MM) have changed dramatically over the past decade. Thus, the role of hematopoietic stem cell transplantation (HCT) must be considered in the context of this evolution. In this evidence-based review, we have critically analyzed the data from the most recent clinical trials to better understand how to incorporate HCT and when HCT is indicated. We have provided our recommendations based on strength of evidence with the knowledge that ongoing clinical trials make this a dynamic field. Within this document, we discuss the decision to proceed with autologous HCT, factors to consider before proceeding to HCT, the role of tandem autologous HCT, post-HCT maintenance therapy, and the role of allogeneic HCT for patients with MM.

show abstract

“…In the United States, 20,000 new cases of MM are diagnosed every year, with about 11,000 deaths by this disease in the same period of time [33, 35]. …”

Section: Ctas Expression In Multiple Myelomamentioning

confidence: 99%

“…Regardless of prognostic factors, MM remains incurable with median overall survival of 3–5 years [32, 35, 37–40]. Although it is possible to obtain complete remission of disease in approximately 25–50% of patients with initial diagnosis (treated with high-dose melphalan and autologous hematopoietic stem cell transplant), almost all will relapse within 2-3 years [18], suggesting that an effective maintenance therapy is needed to control or slow the progression of the disease [37, 41].…”

Section: Ctas Expression In Multiple Myelomamentioning

confidence: 99%

Cancer/Testis Antigen MAGE-C1/CT7: New Target for Multiple Myeloma Therapy

Carvalho

Vettore

Colleoni

2012

Clinical and Developmental Immunology

View full text Add to dashboard Cite

Cancer/Testis Antigens (CTAs) are a promising class of tumor antigens that have a limited expression in somatic tissues (testis, ovary, fetal, and placental cells). Aberrant expression of CTAs in cancer cells may lead to abnormal chromosome segregation and aneuploidy. CTAs are regulated by epigenetic mechanisms (DNA methylation and acetylation of histones) and are attractive targets for immunotherapy in cancer because the gonads are immune privileged organs and anti-CTA immune response can be tumor-specific. Multiple myeloma (MM) is an incurable hematological malignancy, and several CTAs have been detected in many MM cell lines and patients. Among CTAs expressed in MM we must highlight the MAGE-C1/CT7 located on the X chromosome and expressed specificity in the malignant plasma cells. MAGE-C1/CT7 seems to be related to disease progression and functional studies suggests that this CTA might play a role in cell cycle and mainly in survival of malignant plasma cells, protecting myeloma cells against spontaneous as well as drug-induced apoptosis.

show abstract

Multiple Myeloma

Cited by 58 publications

References 105 publications

Survival of Multiple Myeloma Patients Aged 65-70 Years in the Era of Novel Agents and Autologous Stem Cell Transplantation

Survival of Multiple Myeloma Patients Aged 65-70 Years in the Era of Novel Agents and Autologous Stem Cell Transplantation

Hematopoietic Stem Cell Transplantation for Multiple Myeloma: Guidelines from the American Society for Blood and Marrow Transplantation

Cancer/Testis Antigen MAGE-C1/CT7: New Target for Multiple Myeloma Therapy

Contact Info

Product

Resources

About